Evidence map›Paper›PMID 42587283›Full record

ArticleBMC psychiatry2026

A novel perspective on biomarkers of neurodegeneration and neuroinflammation in first episode psychosis: a cross-sectional study.

Valeria Zakurazhnaya, Yana Zorkina, Olga Abramova, Daria Riabinina, Alexandra Ochneva, Valeriya Ushakova, Alexander Reznik, Georgy P Kostyuk, Anna Morozova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Valeria ZakurazhnayaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Yana ZorkinaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia. zorkina.ya@serbsky.ru.ORCID 0000-0003-0247-2717
Olga AbramovaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Daria RiabininaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Alexandra OchnevaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Valeriya UshakovaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Alexander ReznikMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Georgy P KostyukMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.
Anna MorozovaMental-health Clinic, No. 1 named after N.A. Alexeev, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe biological distinction between first-episode psychosis (FEP) and chronic schizophrenia remains unclear. This study investigated a panel of non-canonical serum biomarkers related to neurodegeneration, neuroinflammation, and neurotrophic signaling across these clinical stages.

methodsIn a cross-sectional design, serum concentrations of 18 biomarkers were measured using multiplex immunoassay in 49 FEP patients, 80 patients with chronic schizophrenia (SCH), and 80 healthy controls (CON). Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic), but the distributions of diagnostic groups overlapped substantially.

resultsA distinct biomarker profile was identified in FEP, characterized by significantly lower levels of YKL-40 and BDNF, elevated NCAM-1, decreased TDP-43, and a higher frequency of detectable Aβ1‑42 compared to both SCH and CON groups. In contrast, the SCH group did not differ from CON on most of these markers. Correlation analysis revealed a dense, interconnected biomarker network in SCH, centered on MIF and BDNF, while FEP exhibited a single strong correlation between TDP-43 and YKL-40. Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic) but showed substantial overlap between diagnostic groups.

conclusionThe findings reveal a unique, stage-dependent biological signature in early psychosis, differentiating FEP from both health and the chronic phase of illness. This supports the view of FEP as a distinct pathophysiological state involving dysregulated neuroinflammation, synaptic plasticity, and protein homeostasis, rather than merely a prodromal stage of chronic schizophrenia. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Neuroinflammatory DiseasesPsychotic DisordersSchizophreniaAdultBiomarkersBrain-Derived Neurotrophic FactorChitinase-3-Like Protein 1Cross-Sectional StudiesFemaleHumansMaleYoung AdultBiomarkersBrain-Derived Neurotrophic FactorCHI3L1 protein, humanChitinase-3-Like Protein 1BiomarkersFirst-episode psychosisNeurodegenerationNeuroinflammationSchizophrenia

Identifiers

PMID42587283
PMCPMC13471635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.